Avalo Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.1 | $0.4 | $1.9 | $18.1 | $5.4 |
| Operating income | -$72.9 | -$68.5 | -$27.4 | -$37.4 | -$82.1 |
| Net income | -$78.3 | -$35.1 | -$31.5 | -$41.7 | -$84.4 |
| Cash Flow Statement | |||||
| Free cash flow | — | — | -$30.7 | -$26.8 | -$71.0 |
| Share repurchases | — | — | $3.6 | — | — |
Shares outstanding 53.6M · Free float 91.0%
Annual filing data through FY ended December 31, 2025; float as of September 30, 2026.